| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer
|
Gulen, Ayse Ece
|
|
|
72 |
11 |
p. 3567-3579
|
artikel
|
| 2 |
Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment
|
Zheng, Wei-Wei
|
|
|
72 |
11 |
p. 3739-3753
|
artikel
|
| 3 |
BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy
|
Sun, Steven H.
|
|
|
72 |
11 |
p. 3461-3474
|
artikel
|
| 4 |
Cancer management during the COVID-19 world pandemic
|
Sobhani, Navid
|
|
|
72 |
11 |
p. 3427-3444
|
artikel
|
| 5 |
Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma
|
Chang, Chunxiao
|
|
|
72 |
11 |
p. 3727-3738
|
artikel
|
| 6 |
Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score
|
Zhang, Zhengfeng
|
|
|
72 |
11 |
p. 3635-3649
|
artikel
|
| 7 |
Deciphering the immune reaction leading to spontaneous melanoma regression: initial role of MHCII+ CD163− macrophages
|
Blanc, Fany
|
|
|
72 |
11 |
p. 3507-3521
|
artikel
|
| 8 |
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1
|
Mun, Sung Soo
|
|
|
72 |
11 |
p. 3773-3786
|
artikel
|
| 9 |
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
|
Tachiki, Lisa May Ling
|
|
|
72 |
11 |
p. 3839-3850
|
artikel
|
| 10 |
GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model
|
Hernández-Aceves, Juan A.
|
|
|
72 |
11 |
p. 3825-3838
|
artikel
|
| 11 |
HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia
|
Komic, Hana
|
|
|
72 |
11 |
p. 3559-3566
|
artikel
|
| 12 |
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
|
Schmitt, C.
|
|
|
72 |
11 |
p. 3475-3489
|
artikel
|
| 13 |
Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy
|
Kleber, Julia
|
|
|
72 |
11 |
p. 3867-3873
|
artikel
|
| 14 |
Intravenous injection of tumor extracellular vesicles suppresses tumor growth by reducing the regulatory T cell phenotype
|
Kobayashi, Sanshiro
|
|
|
72 |
11 |
p. 3651-3664
|
artikel
|
| 15 |
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)
|
Vita, Emanuele
|
|
|
72 |
11 |
p. 3803-3812
|
artikel
|
| 16 |
Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics
|
Li, Peipei
|
|
|
72 |
11 |
p. 3453-3460
|
artikel
|
| 17 |
Nomogram for predicting the prognosis of metastatic colorectal cancer patients treated with anti-PD1 therapy based on serum lipids analysis
|
Xiao, Bijing
|
|
|
72 |
11 |
p. 3683-3692
|
artikel
|
| 18 |
PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer
|
Kawasaki, Kento
|
|
|
72 |
11 |
p. 3787-3802
|
artikel
|
| 19 |
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions
|
Uehara, Koki
|
|
|
72 |
11 |
p. 3543-3558
|
artikel
|
| 20 |
Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia
|
Shimazu, Yutaka
|
|
|
72 |
11 |
p. 3861-3865
|
artikel
|
| 21 |
Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer
|
Teramoto, Koji
|
|
|
72 |
11 |
p. 3755-3764
|
artikel
|
| 22 |
Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies
|
Atajanova, Tavus
|
|
|
72 |
11 |
p. 3445-3452
|
artikel
|
| 23 |
Radiation-induced dormancy of intracerebral melanoma: endotoxin inflammation leads to both shortened tumor dormancy and long-term survival with localized senescence
|
Ridwan, Sharif M.
|
|
|
72 |
11 |
p. 3851-3859
|
artikel
|
| 24 |
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis
|
Chao, Jiashuo
|
|
|
72 |
11 |
p. 3717-3726
|
artikel
|
| 25 |
Reconstructing the immunosenescence core pathway reveals global characteristics in pan-cancer
|
Zhang, Yakun
|
|
|
72 |
11 |
p. 3693-3705
|
artikel
|
| 26 |
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer
|
Sugimura, Naomi
|
|
|
72 |
11 |
p. 3593-3608
|
artikel
|
| 27 |
Role of single-cell ferroptosis regulation in intercellular communication and skin cutaneous melanoma progression and immunotherapy
|
Song, Binyu
|
|
|
72 |
11 |
p. 3523-3541
|
artikel
|
| 28 |
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer
|
Ogusu, Shinsuke
|
|
|
72 |
11 |
p. 3765-3772
|
artikel
|
| 29 |
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study
|
Bersanelli, Melissa
|
|
|
72 |
11 |
p. 3707-3716
|
artikel
|
| 30 |
Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate
|
Xu, Tianxiao
|
|
|
72 |
11 |
p. 3491-3505
|
artikel
|
| 31 |
Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)
|
Arendt, A.-M.
|
|
|
72 |
11 |
p. 3813-3824
|
artikel
|
| 32 |
Th1 cytokines in pediatric acute lymphoblastic leukemia
|
Schober, Sarah
|
|
|
72 |
11 |
p. 3621-3634
|
artikel
|
| 33 |
Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study
|
Iwai, Chikako
|
|
|
72 |
11 |
p. 3581-3591
|
artikel
|
| 34 |
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
|
Sauer, Natalia
|
|
|
72 |
11 |
p. 3405-3425
|
artikel
|
| 35 |
Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study
|
Yu, Wenchang
|
|
|
72 |
11 |
p. 3609-3619
|
artikel
|
| 36 |
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
|
Fiala, Ondřej
|
|
|
72 |
11 |
p. 3665-3682
|
artikel
|
Tijdschrift beschrijving